Supreme Court Questions Role Of Preclinical Efficacy Data In IND Process
This article was originally published in The Pink Sheet Daily
Executive Summary
During oral arguments in the Merck KGaA v. Integra case, several justices suggest that preclinical efficacy data are a key consideration during the IND process and may warrant “safe harbor” protection from patent infringement claims under the “Bolar Amendment.”